Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M91,133Revenue $M25,711Net Margin (%)7.8Z-Score2.6
Enterprise Value $M95,453EPS $2.0Operating Margin %11.8F-Score4
P/E(ttm))46.4Cash Flow Per Share $0Pre-tax Margin (%)9.2Higher ROA y-yN
Price/Book4.410-y EBITDA Growth Rate %10.5Quick Ratio0.9Cash flow > EarningsY
Price/Sales3.65-y EBITDA Growth Rate %-9.0Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-31.7ROA % (ttm)3.5Higher Current Ratio y-yN
Dividend Yield %3.9Insider Buy (3m)0ROE % (ttm)8.8Less Shares Outstanding y-yN
Payout Ratio %174Shares Outstanding M1,263ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with AZN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNGeorge Soros 2014-06-30 Buy 0.08%$62.45 - $81.09
($72.26)
$ 71.53-1%New holding, 150000 sh.150,000
AZNMario Gabelli 2014-06-30 Buy 0.02%$62.45 - $81.09
($72.26)
$ 71.53-1%New holding, 40400 sh.40,400
AZNCharles Brandes 2014-06-30 Reduce-0.78%$62.45 - $81.09
($72.26)
$ 71.53-1%Reduce -71.06%386,058
AZNJoel Greenblatt 2014-06-30 Sold Out -0.09%$62.45 - $81.09
($72.26)
$ 71.53-1%Sold Out0
AZNNWQ Managers 2014-06-30 Reduce-0.01%$62.45 - $81.09
($72.26)
$ 71.53-1%Reduce -24.55%64,475
AZNJohn Hussman 2014-03-31 Add0.96%$58.51 - $68.15
($64.29)
$ 71.5311%Add 714.29%228,000
AZNDavid Dreman 2014-03-31 Add0.14%$58.51 - $68.38
($64.41)
$ 71.5311%Add 26.61%135,439
AZNJoel Greenblatt 2014-03-31 Buy 0.09%$58.51 - $68.38
($64.41)
$ 71.5311%New holding, 95518 sh.95,518
AZNHOTCHKIS & WILEY 2014-03-31 Sold Out -0.93%$58.51 - $68.38
($64.41)
$ 71.5311%Sold Out0
AZNCharles Brandes 2014-03-31 Reduce-0.84%$58.51 - $68.15
($64.29)
$ 71.5311%Reduce -46.73%1,333,894
AZNDavid Dreman 2013-12-31 Reduce-0.34%$49.72 - $59.5
($54.28)
$ 71.5332%Reduce -40.32%106,975
AZNHOTCHKIS & WILEY 2013-12-31 Reduce-0.3%$49.72 - $59.5
($54.28)
$ 71.5332%Reduce -24.9%3,689,214
AZNJohn Hussman 2013-12-31 Reduce-0.11%$49.72 - $59.5
($54.28)
$ 71.5332%Reduce -58.82%28,000
AZNCharles Brandes 2013-09-30 Add0.12%$47.88 - $52.08
($50.24)
$ 71.5342%Add 7.92%2,381,040
AZNJohn Hussman 2013-09-30 Reduce-0.66%$47.88 - $52.08
($50.24)
$ 71.5342%Reduce -81.87%68,000
AZNHOTCHKIS & WILEY 2013-06-30 Add0.68%$47.22 - $53.01
($50.92)
$ 71.5340%Add 131.18%4,944,742
AZNJohn Hussman 2013-06-30 Reduce-1.02%$47.22 - $53.01
($50.92)
$ 71.5340%Reduce -59.76%375,000
AZNJoel Greenblatt 2013-06-30 Sold Out -0.24%$47.22 - $53.01
($50.92)
$ 71.5340%Sold Out0
AZNNWQ Managers 2013-03-31 Buy 0.03%$44.67 - $50.06
($47.4)
$ 71.5351%New holding, 78400 sh.78,400
AZNJohn Hussman 2013-03-31 Reduce-0.74%$44.67 - $50.06
($47.4)
$ 71.5351%Reduce -38.8%932,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AZN Mario Gabelli 2014-06-3040,40000.02New Buy
AZN George Soros 2014-06-30150,0000.010.08New Buy
AZN - CALLDaniel Loeb 2014-06-301,000,0000.080.91
AZN John Hussman 2014-06-30223,5000.021.3-1.97%
AZN David Dreman 2014-06-30117,8320.010.66-13%
AZN NWQ Managers 2014-06-3064,4750.010.05-24.55%
AZN Charles Brandes 2014-06-30386,0580.030.35-71.06%
AZN Joel Greenblatt 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about AZN :

    Quarterly/Annual Reports about AZN:

      News about AZN:

      Articles On GuruFocus.com
      Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
      I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
      A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
      Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 
      Abbott Capturing Incremental Market Share Mar 18 2014 
      Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
      10 British Stocks to Consider Feb 20 2014 
      Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
      AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 

      More From Our Partners
      Update: AstraZeneca Receives Positive EMA Recommendation For Olaparib Oct 26 2014 - SEEKINGALPHA

      More From Other Websites
      Pfizer beats Q3 earnings forecasts - is that enough? Oct 28 2014
      Pfizer Beats Earnings, But Lacks Year-over-Year EPS Growth Oct 28 2014
      4 Stocks, 4 trades: BWLD, PFE, COH & KSS Oct 28 2014
      Indian drugmaker Ranbaxy still has exclusive rights for Nexium generic -CEO Oct 28 2014
      How Pfizer Inc. Could Push AstraZeneca plc Down To 3,100p Oct 28 2014
      Cramer: Pfizer flatlining Oct 28 2014
      Pfizer earnings edge higher on strong vaccine sales Oct 28 2014
      Pfizer beats forecasts on demand for cancer drugs Oct 28 2014
      AstraZeneca's Lynparza a Step Closer to European Approval Oct 27 2014
      Ex-Bank of New York Mellon employee pleads guilty to insider trading Oct 24 2014
      Market report: AstraZeneca slips on Pfizer buy back Oct 24 2014
      Ex-Bank of New York Mellon trader pleads guilty to insider trading Oct 24 2014
      Bristol-Myers Beats Q3 Views As Eliquis Revives Oct 24 2014
      Bristol-Myers Beats on Q3 Earnings, Maintains Guidance Oct 24 2014
      Pfizer (PFE) $11 Billion Stock Repurchase Plan May End AstraZeneca (AZN) Bid Oct 24 2014
      AstraZeneca cancer drug pipeline gets boost from European green light Oct 24 2014
      Lynparza™ (olaparib) receives positive CHMP opinion in the EU for the maintenance treatment of... Oct 24 2014
      AstraZeneca ovarian cancer drug wins European green light Oct 24 2014
      Weaker travel and leisure stocks push FTSE lower Oct 24 2014
      Pfizer's $11 bln buyback plan deflates AstraZeneca bid hopes Oct 24 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK